Hyo Park

Hyo Min Park is a Co-Founder of GenEdit, a company focused on developing innovative therapies through targeted delivery of genetic medicines.2 She holds a Ph.D. in Biology from the University of California, Berkeley, which she completed between 2011 and 2016.1 Park co-founded GenEdit in April 2016 along with Kunwoo Lee and Niren Murthy, collaborating closely with Nobel Laureate Jennifer Doudna during their time at UC Berkeley.23

GenEdit aims to overcome limitations in genetic medicine by developing safe and efficient delivery systems for CRISPR/Cas9 and other gene therapies.3 The company's platform is designed to deliver various genetic medicines, proteins, and drug molecules to their targets within cells.3

Prior to co-founding GenEdit, Park was a Ph.D. student at UC Berkeley from January 2011 to May 2016.1 Her research focused on nanoparticles and metabolic drug discovery, which laid the foundation for GenEdit's innovative approach to gene therapy delivery.3

Park's work at GenEdit is driven by the goal of helping millions of people struggling with genetic disorders.3 The company has made significant progress in developing delivery technologies that are safer, more efficacious, and more targeted than current approaches in gene therapy.3